Konieczkowski DJ, Garraway LA. Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones. Cell Res. 2013;23(1):13-4. doi:10.1038/cr.2012.115
Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-96. doi:10.1200/JCO.2010.33.2312
Adams DJ, Dai M, Pellegrino G, et al. Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs. Proc Natl Acad Sci U S A. 2012;109(38):15115-20. doi:10.1073/pnas.1212802109
Jalili A, Wagner C, Pashenkov M, et al. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. J Natl Cancer Inst. 2012;104(21):1673-9. doi:10.1093/jnci/djs373
Van Allen EM, Pomerantz M. Moving toward personalized medicine in castration-resistant prostate cancer. Urol Clin North Am. 2012;39(4):483-90. doi:10.1016/j.ucl.2012.07.005
Adams DJ, Bošković ŽV, Theriault JR, et al. Discovery of small-molecule enhancers of reactive oxygen species that are nontoxic or cause genotype-selective cell death. ACS Chem Biol. 2013;8(5):923-9. doi:10.1021/cb300653v
Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J Clin Oncol. 2013;31(15):1803-5. doi:10.1200/JCO.2013.49.4799
Olson DE, Wagner FF, Kaya T, et al. Discovery of the first histone deacetylase 6/8 dual inhibitors. J Med Chem. 2013;56(11):4816-20. doi:10.1021/jm400390r
Yuan Y, Tang AJ, Castoreno AB, et al. Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells. Cell Death Dis. 2013;4:e690. doi:10.1038/cddis.2013.191
Serra V, Eichhorn PJA, GarcÃa-GarcÃa C, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest. 2013;123(6):2551-63. doi:10.1172/JCI66343